Raymond James & Associates Has $4.14 Million Stake in Genmab A/S (NASDAQ:GMAB)

Raymond James & Associates raised its position in Genmab A/S (NASDAQ:GMAB) by 2.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 169,747 shares of the company’s stock after purchasing an additional 3,598 shares during the period. Raymond James & Associates’ holdings in Genmab A/S were worth $4,138,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GMAB. DDD Partners LLC acquired a new position in shares of Genmab A/S in the 2nd quarter worth approximately $8,860,000. Capital International Investors increased its stake in shares of Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in shares of Genmab A/S in the 2nd quarter valued at $1,354,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Price Performance

NASDAQ GMAB opened at $22.56 on Friday. Genmab A/S has a 1 year low of $22.22 and a 1 year high of $32.89. The firm has a market cap of $14.93 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 0.66 and a beta of 0.99. The company has a fifty day moving average price of $24.88 and a 200-day moving average price of $26.60.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. On average, research analysts anticipate that Genmab A/S will post 1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GMAB. Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Finally, Truist Financial decreased their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.